About this trial
This trial looks at how different doses of immunotherapy medicines can affect people with solid tumor cancers. It aims to understand if higher doses cause more immune-related side effects compared to lower doses. The study includes two groups of participants who will receive different treatments to see how they respond.
The trial's ID number is NCT07174453. It is a Phase 3 trial, which means it is testing how well the treatment works and its safety. The study is regulated by the FDA and aims to include about 192 participants.
Who can join
Adults aged 18 and older can join. Both men and women are welcome. Participants must have a confirmed diagnosis of solid tumor cancer and be eligible for certain immunotherapy treatments. Some conditions, like current pregnancy or other ongoing treatments, may prevent someone from joining. The trial team will check if each person is eligible.
Condition
Solid Tumor Malignancies
Age group
Adult, Older adult
The study team makes the final call on eligibility.
What happens in the study
Participants will be placed in one of two groups by chance. One group will receive Pembrolizumab at a lower dose every 3 weeks and Nivolumab at a lower dose every 2 weeks. The other group will receive higher doses of both medicines at different intervals. Everyone will receive treatment for about 12 months to monitor their progress and any side effects.
Where
This trial is running at 1 location in the United States. It is currently recruiting.
The University of Kansas Cancer Center
Westwood, Kansas